Home
BioVision

BioVision Market Share Analysis for November 2025

Abcam, the leading supplier of protein research tools to life scientists. Abcam offers high-quality biological reagents and tools including antibodies, proteins, assays, cell lines and lysates.

Science and Education > Biology

Domainbiovision.com

Year Founded1997

Employees51 - 200

Annual Revenue$25M - $50M

BioVision

BioVision (including company regionals)

biovision.com

See more website traffic and engagement information

BioVision Revenue up to November 2025 is 25M - 50M

revenue generated by BioVision top domains

BioVision top domains revenue over 3 years

Revenue for BioVision top domains

biovision.com25M - 50M

See more with Sales Intelligence

Total visits to BioVision's top domains

Understand BioVision market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in BioVision's top domains

Analyze BioVision engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on BioVision's top domains

See how BioVision keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

BioVision top competitors by domain

Top similar sites in November 2025, ranked by their affinity

abcam.comCompany NameAbcamEmployees1001 - 5000HQUnited Kingdom, CambridgeAnnual revenue$500M - $1BTotal visits890.4KScience and Education > Biology

Top technologies used by BioVision

These are the website technologies, by industry, used by BioVision top domains

Advertising (9)

DoubleClick

Social (7)

Google+ Platform

Widget (5)

reCAPTCHA

Payment & Currencies (4)

Cart Functionality

More Technologies

10

See all

News & Signals from BioVision

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBiovision launched Cas9 recombinant protein for genome editing on Jan 1st '17.Moreover, in 2017, BioVision Inc. launched Cas9 recombinant protein for genome editing.

NewsAbcam acquired Biovision for $340M on Oct 27th '21.Abcam plc (“Abcam”, “the Company” or “the Group”) (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”).

NewsBiovision launched Cas9 recombinant protein for genome editing on Jan 1st '17.Moreover, in 2017, BioVision Inc. launched Cas9 recombinant protein for genome editing.